Elevated K-ras activity with cholestyramine and lovastatin, but not konjac mannan or niacin in lung--Importance of mouse strain

Biochemical Pharmacology

Volumn 72, Issue 12, 2006, Pages 1749-1755

  Calvert, Richard J ^a,b   Tepper, Shirley ^c   Kammouni, Wafa ^b   Anderson, Lucy M ^b   Kritchevsky, David ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

Cholesterol; Cholestyramine; K ras activity; Konjac mannan; Lovastatin; Lung; Mice; Niacin

Indexed keywords

CHOLESTEROL; COLESTYRAMINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; HYPOCHOLESTEROLEMIC AGENT; K RAS PROTEIN; MEVINOLIN; NICOTINIC ACID; PROPOL A; RAF PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; BODY WEIGHT; CANCER INHIBITION; CHEMOLUMINESCENCE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; INTRACELLULAR MEMBRANE; LIPID ANALYSIS; LUNG CARCINOGENESIS; LUNG PARENCHYMA; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOTTING, WESTERN; BODY WEIGHT; CHOLESTEROL; CHOLESTYRAMINE; ELECTROPHORESIS, AGAR GEL; LOVASTATIN; LUNG; MALE; MANNANS; MICE; MICE, INBRED C57BL; NIACIN; RAS PROTEINS; SPECIES SPECIFICITY;

EID: 33751351870     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.08.026     Document Type: Article

References (34)

1. Kritchevsky S.B., and Kritchevsky D. Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 12 (1992) 391-416
2. Calvert R.J., Ramakrishna G., Tepper S., Diwan B.A., Anderson L.M., and Kritchevsky D. Alterations in membrane-bound and cytoplasmic K-ras protein levels in mouse lung induced by treatment with lovastatin, cholestyramine, or niacin: effects are highly mouse strain dependent. Biochem Pharmacol 64 (2002) 41-48
3. Calvert R.J., Tepper S., Diwan B.A., Anderson L.M., and Kritchevsky D. Treatment with lovastatin, cholestyramine or niacin alters K-ras membrane association in mouse lung in a strain-dependent manner: results in females. Biochem Pharmacol 66 (2003) 393-403
4. Zhang Z., Wang Y., Vikis H.G., Johnson L., Liu G., Li J., et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 29 (2001) 25-33
5. Kammouni W., Ramakrishna G., Sithanandam S., Smith G.T., Fornwald L.W., Masuda A., et al. Increased K-ras protein and activity in mouse and human lung epithelial cells at confluence. Cell Growth Diff 13 (2002) 441-448
6. Ramakrishna G., Sithanandam G., Cheng R.Y., Fornwald L.W., Smith G.T., Diwan B.A., et al. K-ras p21 expression and activity in lung and lung tumors. Exp Lung Res 26 (2000) 659-671
7. Friis S., Poulsen A.H., Johnsen S.P., McLaughlin J.K., Fryzek J.P., Dalton S.O., et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 114 (2005) 643-647
8. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., et al. Statins and risk of colorectal cancer. NEJM 352 (2005) 2184-2192
9. Neil H.A., Hawkins M.M., Durrington P.N., Betteridge D.J., Capps N.E., and Humphries S.E. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolemia: a prospective registry study. Atherosclerosis 179 (2005) 293-297
10. Hawk M.A., Cesen K.T., Siglin J.C., Stoner G.D., and Ruch R.J. Inhibition of lung tumor growth in vitro and mouse lung tumor formation by lovastatin. Cancer Lett 109 (1996) 217-222
11. Paragh G., Foris G., Paragh Jr. G., Seres I., Karanyi Z., Fulop P., et al. Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats. Cancer Lett 222 (2005) 17-22
12. Shibata M.A., Ito Y., Morimoto J., and Otsuki Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 25 (2004) 1887-1898
13. Vuksan V., Sievenpiper J.L., Owen R., Swilley J.A., Spadafora P., Jenkins D.J., et al. Beneficial effects of viscous dietary fiber from konjac-mannan in subjects with the insulin resistance syndrome. Diab Care 23 (2000) 9-14
14. Reeves P.G., Nielsen F.H., and Fahey Jr. G.C. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc committee on the reformulation of the AIN-76A rodent diet. J Nutr 123 (1993) 1939-1951
15. Khan S.G., Saxena R., Bickers D.R., Mukhtar H., and Agarwal R. Inhibition of ras p21 membrane localization and modulation of protein kinase C isoenzyme expression during regression of chemical carcinogen-induced murine skin tumors by lovastatin. Mol Carcinogen 12 (1995) 205-212
16. Calvert R.J., Kammouni W., and Kikawa K.D. Optimization of a nonradioactive method for consistent and sensitive determination of activated K-ras protein. Anal Biochem 343 (2005) 283-292
17. Quazi S., Yokogoshi H., and Yoshida A. Effect of dietary fiber on hypercholesterolemia induced by dietary PCB or cholesterol in rats. J Nutr 113 (1983) 1109-1118
18. Wu J., and Peng S.S. Comparison of hypolipidemic effect of refined Konjac meal with several common dietary fibers and their mechanisms of action. Biomed Environ Sci 10 (1997) 27-37
19. Walsh D.E., Yaghoubian V., and Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obesity 8 (1984) 289-293
20. Ebihara K., and Kiriyama S. Prevention of cholesterol gallstones by a water-soluble dietary fiber, Konjac Mannan, in mice. Nutr Rep Int 32 (1985) 223-229
21. Ramakrishna G., Perella C., Birely L., Diwan B.A., Fornwald L., and Anderson L.M. Decrease in K-ras p21 and increase in Raf1 and activated Erk1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8 tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 179 (2002) 21-39
22. Nigro N.D., Bhadrachari N., and Chomchai C. A rat model for studying colonic cancer: effect of cholestyramine on induced tumors. Dis Colon Rectum 16 (1973) 438-443
23. Melhem M.F., Gabriel H.F., Eskander E.D., and Rao K.N. Cholestyramine promotes 7,12 dimethybenzanthracene induced mammary cancer in Wistar rats. Br J Cancer 56 (1987) 45-48
24. Clearfield M., Downs J.R., Weis S., Whitney E.J., Kruyer W., Shapiro D.R., et al. Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Women Health Gend Based Med 10 (2001) 971-981
25. Coogan P.F., Rosenberg L., Palmer J.R., Strom B.L., Zauber A.G., and Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology 13 (2002) 262-267
26. Downs J.R., Clearfield M., Tyroler H.A., Whitney E.J., Kruyer W., Langendorfer A., et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 87 (2001) 1074-1079
27. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
28. Kaye J.A., Meier C.R., Walker A.M., and Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer 86 (2002) 1436-1439
29. Pedersen T.R., Wilhemsen L., Faergeman O., Starndberg T.E., Thorgeirsson G., Troedsson L., et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 86 (2000) 257-262
30. Pfeffer M.A., Keech A., Sacks F.M., Cobbe S.M., Tonkin A., Byington R.P., et al. Safety and tolerability of pravastatin in long-term clinical trials-Prospective pravastatin pooling (PPP) project. Circulation 105 (2002) 2341-2346
31. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
32. Strandberg T.E., Pyorala K., Cook T.J., Wilhemsen L., Faergeman O., Thorgeirsson G., et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364 (2004) 771-777
33. Bonovas S., Filioussi K., Tsavaris N., and Sitaras N.M. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23 (2005) 8606-8612
34. Jacobs E.J., Rodriguez C., Brady K.A., Connell C.J., Thun M.J., and Calle E.E. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States Cohort. J Natl Cancer Inst 98 (2006) 69-72